

## **Product datasheet for TL300106V**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **ZNF606 Human shRNA Lentiviral Particle (Locus ID 80095)**

#### **Product data:**

**Product Type:** shRNA Lentiviral Particles

**Product Name:** ZNF606 Human shRNA Lentiviral Particle (Locus ID 80095)

Locus ID: 80095 Synonyms: ZNF328

**Vector:** pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ZNF606 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC036570, NM 025027, NM 001348022, NM 001348023, NM 001348024, NM 001348025,

NM 025027.1, NM 025027.2, NM 025027.3, NM 025027.4, BC037209, BC037209.1, BC022533

UniProt ID: Q8WXB4

**Summary:** This gene encodes a zinc finger protein containing a Kruppel-associated box (KRAB) domain

at its N-terminus, followed by contiguous C2H2 zinc finger motifs. The encoded protein is a

nuclear protein that can act as a transcriptional repressor of growth factor-mediated

signaling pathways in a reporter gene assay. This protein has been shown to interact with the SRY-box 9 gene product, and suppresses its transcriptional activity by inhibiting its DNA binding activity. Reduced expression of this gene promotes chondrocyte differentiation. Alternative splicing results in multiple transcript variants encoding different isoforms.

[provided by RefSeq, Dec 2016]

**shRNA Design:** These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







# Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).